Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy. - Wikidata - wikimedia - TriplyDB

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

http://www.wikidata.org/entity/Q42501180

about

Tau PET imaging: present and future directions.Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.Imaging and fluid biomarkers in frontotemporal dementia.Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?Imaging tau pathology in Parkinsonisms.The emerging role of PET imaging in dementia.18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.New advances in tau imaging in parkinsonism.[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy.Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau.Small-molecule PET Tracers for Imaging Proteinopathies.PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms.Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration.Molecular imaging: What is right and what is an illusion?Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology.Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding.Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy.Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?The development and validation of tau PET tracers: current status and future directions Imaging Protein Misfolding in the Brain Using β-Sheet Ligands [F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review

P2860

Q34680852-DB0AFBDE-2637-4D46-B651-B6C48EEC9A91 Q37731710-F1215B45-99AA-464D-93BA-0C060F3F9C95 Q38640294-BAE17D28-0D67-4FB4-84FB-82F4E3242135 Q38670219-8E969033-D489-4660-8C1C-44E8D4B3B37E Q39303669-45CF7F4B-3C1A-4E81-ADA1-B6EE8D383D0D Q39419877-8EDA7CD2-15B4-41A0-A156-55D7330BCD1A Q42701971-566737A0-6789-4339-8CBB-EA755E9C3295 Q46616293-90D94333-A38A-471A-ABBB-1232BD196B16 Q47140361-41A7D06C-813F-46A6-A4F5-33462A32BEDF Q47329627-50FA7A13-B24D-436E-8EBB-EF9DFFD78F92 Q47547648-71F8136A-A92F-42A7-AB44-9B5382AD6286 Q47739900-C6FE2018-D124-434B-B62F-CDE6C16A59A5 Q47926474-E3315FEA-237F-4804-8E78-33CAC6417A79 Q48346682-8AF43BA4-A18A-479B-BD6C-9DEA31027B7D Q49295547-18C0F0F1-E17B-44AB-A8F9-6ED2B0F08D7E Q49900567-0161065C-DC9D-4A78-A310-6CE3BDF20974 Q52344625-DC00A8DD-A923-4025-9200-2643E6ABBAFA Q55031324-83DA18BB-97DB-4D48-987D-FEA78EF7FAD3 Q55254017-6BB1035C-5BED-4912-ADCF-E91242CC317C Q55339752-F705661C-1C46-421C-B921-3F1BECC01CD7 Q55416644-12BAFAD1-2EA0-463F-8DDA-D10DC224E4E7 Q55494083-0CE857A3-B608-4B03-8D99-D67700E2CC76 Q55497377-A2EF9588-35AE-42CA-90AF-D9BCCEF6A2D6 Q56594907-1B467077-5761-46BA-AD57-787B45676B9F Q57168250-E469DFB6-E680-4CB4-8AC2-6673CF5B4122 Q58794629-B2D6148B-30A2-4B13-B03B-1F79CDC0C9A7

P2860

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

http://www.wikidata.org/entity/Q42501180

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

@en

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

@nl

type

label

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

@en

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

@nl

prefLabel

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

@en

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

@nl

P1433

Q42501180-BA21AA2B-FE5F-46FC-9D53-FBE2C3E014C5

P1476

Q42501180-6E636F93-8C70-4D56-B072-CB9616EE7231

P2093

Q42501180-0053C388-EB84-4649-9F18-5ACB753A387D

Q42501180-0817E758-65DF-423D-A5E2-565B47FB1E39

Q42501180-15A0A61A-C469-4105-82F9-005F73A99272

Q42501180-1F658307-13D3-4111-9076-EC0CFE209219

Q42501180-2061BE39-0203-437D-AA65-D9B6CF5515A7

Q42501180-6161B4CF-C62E-4D83-977E-AF08D6476D59

Q42501180-7063F133-F32B-4FE8-8D71-864903D177D2

Q42501180-8968052D-9552-47E7-841F-054367E532D0

Q42501180-988D9036-7235-464E-9F45-3EA4F123F221

Q42501180-E99A4326-4C97-42B6-89B4-5F3635B81AC9

P2860

Q42501180-1EFED1DA-3E47-4932-9F77-D6BEB65919F9

Q42501180-2384737D-E88E-4D85-B712-FEE38E30CCFB

Q42501180-343E5904-02B1-45B0-AA4C-4799015739F4

Q42501180-37463336-019A-4F0A-B697-7AA32938D785

Q42501180-4A7CD180-94FD-4FEA-B41C-EADD5A891B71

Q42501180-52A2DE4F-FDED-4708-BB03-10548BFC5D20

Q42501180-5BB450CE-D988-4757-A73B-C29EF8097586

Q42501180-740CD9A4-B979-4D70-BFF0-054AE6D94251

Q42501180-89C91DB2-CE16-4F78-AA79-CE1EE14AA986

Q42501180-9C250709-1EE4-48CB-A075-9CB9DA16DB4B

P304

Q42501180-CB4847C9-6EAB-4C67-A435-6F4242E7A8D0

P31

Q42501180-45313E67-9676-4C35-AC61-A3D942C92DE9

P356

Q42501180-65D387E7-E2C8-435D-821D-570F44991982

P433

Q42501180-79BB0C55-FD87-43A7-B331-D87B89A7C2C6

P478

Q42501180-6F3B347F-1AFE-4E0D-9B92-263E6FA1FD41

P50

Q42501180-47E49411-CD0D-4232-8B1E-D51064CC66BB

Q42501180-58B2B48B-5CB9-418F-9052-EDD1C705D1DA

P577

Q42501180-A73ED053-791A-41D9-B7D2-392E5B36A8EB

P698

Q42501180-F0F32C6E-DC12-401D-8420-D6F2ADD4A3DD

P356

P1433

European Journal of Neurology

P1476

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

@en

P2093

A Ishiki

http://www.w3.org/2001/XMLSchema#string

C C Rowe

http://www.w3.org/2001/XMLSchema#string

H Arai

http://www.w3.org/2001/XMLSchema#string

K Furukawa

http://www.w3.org/2001/XMLSchema#string

M Tashiro

http://www.w3.org/2001/XMLSchema#string

N Tomita

http://www.w3.org/2001/XMLSchema#string

R Harada

http://www.w3.org/2001/XMLSchema#string

S Furumoto

http://www.w3.org/2001/XMLSchema#string

V L Villemagne

http://www.w3.org/2001/XMLSchema#string

Y Kudo

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Tau imaging: early progress and future directions

Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

PET Imaging of Tau Pathology in Alzheimer's Disease and Tauopathies.

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography.

Tau positron emission tomographic imaging in aging and early Alzheimer disease

P304

130-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ENE.13164

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Nobuyuki Okamura

P577

2016-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27797445

http://www.w3.org/2001/XMLSchema#string